#United States #Santa Clarita #Autoimmune Diseases #SetPoint Medical #Dan Dearen

SetPoint Medical Welcomes Dan Dearen to Its Board of Directors

SetPoint Medical, a company specializing in medical technology aimed at improving the lives of those suffering from chronic autoimmune diseases, has announced the appointment of Dan Dearen to its Board of Directors. This strategic move comes as the company looks to enhance its commercial operations and advance its innovative treatment pipeline.

A Seasoned Leader in Medical Technology

Dan Dearen brings nearly 40 years of executive experience in the medical device and life sciences sectors. His track record showcases a deep understanding of building and scaling companies within the medical technology field, particularly in the context of financial leadership and operational efficiency. As SetPoint Medical embarks on its next phase of growth, Dearen’s expertise will be invaluable in guiding the company’s operational strategies and strengthening its market position.

Achievements in Previous Roles

Before joining SetPoint, Dearen held significant roles at Axonics, Inc., a company focusing on innovative therapies for bladder and bowel dysfunction. As the co-founder and CFO, he played a critical role in Axonics’ initial public offering in 2018, overseeing the development of its financial and operational infrastructure and facilitating rapid commercial growth. His leadership contributed to Axonics becoming a notable player in the medical technology landscape, ultimately leading to its acquisition by Boston Scientific for a staggering $3.7 billion in November 2024.

Dearen’s past also includes serving as the Chief Operating and Financial Officer at Vessix Vascular, which was similarly acquired by Boston Scientific for $425 million in 2012. These experiences highlight his capacity to guide companies through key inflection points, ensuring they achieve commercial success while delivering innovative healthcare solutions.

What This Means for SetPoint Medical

“Dan’s extensive financial, operational, and strategic experience will be invaluable as we scale SetPoint Medical’s commercial operations and advance our pipeline,” stated Murthy V. Simhambhatla, Ph.D., the president and CEO of SetPoint Medical. With Dearen on the board, the company aims to redefine treatment options for chronic autoimmune diseases, adding a robust layer of strategic guidance as they explore new pathways for technology implementation.

Dearen's sentiment resonates with the vision SetPoint Medical has set forth: “I’m honored to join the board as the company advances toward its next phase of growth,” he expressed. His anticipation of guiding the company towards impactful milestones further solidifies the partnership between him and SetPoint.

SetPoint Medical's Future Direction

SetPoint Medical is committed to revolutionizing treatment for chronic autoimmune diseases through its FDA-approved SetPoint® System. This pioneering neuroimmune modulation therapy presents a device-based alternative aimed at those who do not find relief with standard therapies, such as biologic or targeted drug treatments. By utilizing its proprietary neurostimulation platform designed to engage anti-inflammatory pathways in the vagus nerve, the company strives to mitigate inflammation and restore immunologic balance effectively.

As SetPoint employs its integrated system for conditions such as rheumatoid arthritis and looks to expand to diseases like multiple sclerosis and Crohn's disease, the addition of seasoned professionals like Dearen is pivotal in navigating the complexities of the medical technology landscape.

In conclusion, SetPoint Medical’s appointment of Dan Dearen not only reinforces its commitment to advancing healthcare technology but also sets the stage for potential breakthroughs in how chronic autoimmune conditions are addressed, ensuring better care for patients in need. For more information on their innovative solutions, visit SetPoint Medical's website.